The Relationship between the Levels of Serum Cystatin C and the Occurrence of the No-Reflow Phenomenon during Primary Percutaneous Coronary Interventions

Abstract

Background:The best treatment of ST-segment elevation myocardial infarction (STEMI) is reperfusion of ischemic myocardium as soon as possible. Primary percutaneous coronary intervention (PPCI) has become the preferred strategy for reperfusion and the current standard care for STEMI. Noreflow is clinically important as it is associated with cardiac failure, malignant arrhythmias and in-hospital and long-term mortality. Cystatin C is a potent inhibitor of lysosomal proteinases and found in virtually all tissues and body fluids. Aim of Study:To assess the relationship between the level of Cystatin C and the occurrence of no-reflow during primary PCI in the setting of STEMI.

A biomarker for estimating no-reflow phenomenon in PCI-treated non-ST-segment elevation myocardial infarction patients: serum Cystatin C

“…Another study found an independent association between Cys-C and NRP in 68 STEMI patients. 31 In our study, we observed similar results in patients with NST-ACS. Several mechanisms may elucidate the potential role of Cys-C in patients with ACS and its association with NRP.…”